Bleeding Disorders Associated with Cancer Dysproteinemias

Part of the Cancer Treatment and Research book series (CTAR, volume 148)

Acquired coagulation abnormalities are not infrequently detected in the laboratory evaluation of patients with paraproteinemias; however, clinically evident manifestations are observed in only 10% of such patients [1]. The hemorrhages observed with these abnormalities are rarely spontaneous, but often associated with surgical procedures. Hemostatic abnormalities have been reported in patients with primary AL amyloidosis, Waldenström macroglobulinemia, multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS).


Multiple Myeloma Cerebral Amyloid Angiopathy Thrombin Time Fibrin Polymerization Primary Amyloidosis 


  1. 1.
    Liebman HA. Hemostatic defects associated with dysproteinemias. In: R. Hoffman et al., eds. Hematology: basic principles and practice, 3rd edn. New York: Churchill Livingstone, 2000;1996–1999Google Scholar
  2. 2.
    Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33Google Scholar
  3. 3.
    García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115(3):575–82PubMedCrossRefGoogle Scholar
  4. 4.
    Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59PubMedGoogle Scholar
  5. 5.
    Perkins HA, MacKenzie MR, Fudenberg HH. Hemostatic defects in dysproteinemias. Blood 1970;35(5):695–707PubMedGoogle Scholar
  6. 6.
    Gamba G, Montani N, Anesi E, et al. Clotting alterations in primary systemic amyloidosis. Haematologica 2000;85(3):289–92PubMedGoogle Scholar
  7. 7.
    Mumford A, O’Donnell J, Gillmore J, et al. Bleeding symptoms and coagulation abnormalities in 337 patients with Al-amyloidosis. Br J Haematol 2000;110:454–460PubMedCrossRefGoogle Scholar
  8. 8.
    Kyrtsonis M, Vassilakopoulos T, Angelopuolou M, et al. Waldenstrom’s macoglobulinemia: clinical course and prognostic factors in 60 patients. Ann Hematol 2001;80:722–727PubMedCrossRefGoogle Scholar
  9. 9.
    Sucker C, Hetzel GR, Grabensee B, et al. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis 2006;47(6):947–55PubMedCrossRefGoogle Scholar
  10. 10.
    Hoshino Y, Hatake K, Muroi K, et al. Bleeding tendency caused by the deposit of amyloid substance in the perivascular region. Intern Med 1993;32(11):879–81PubMedCrossRefGoogle Scholar
  11. 11.
    Choufani E, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to highdose chemotherapy. Blood 2001;97:1885–1887PubMedCrossRefGoogle Scholar
  12. 12.
    Furie B, Voo L, McAdam KP, et al. Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 1981;304(14):827–30PubMedCrossRefGoogle Scholar
  13. 13.
    Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. N Engl J Med 1977;297(2):81–5PubMedCrossRefGoogle Scholar
  14. 14.
    Galbraith PA, Sharma N, Parker WL, et al. Acquired factor X deficiency. Altered plasma antithrombin activity and association with amyloidosis. JAMA 1974;230(12):1658–60PubMedCrossRefGoogle Scholar
  15. 15.
    Greipp PR, Kyle RA, Bowie EJ. Factor X deficiency in primary amyloidosis: resolution after splenectomy. N Engl J Med 1979;301(19):1050–1PubMedCrossRefGoogle Scholar
  16. 16.
    Rosenstein ED, Itzkowitz SH, Penziner AS, et al. Resolution of factor X deficiency in primary amyloidosis following splenectomy. Arch Intern Med 1983;143(3):597–9PubMedCrossRefGoogle Scholar
  17. 17.
    Gabriel DA, Smith LA, Folds JD, et al. The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med 1983;101(4):545–52PubMedGoogle Scholar
  18. 18.
    Korsan-Bengsten K, Hjort PF, Ygge J. Acquired factor X deficiency in a patient with amyloidosis. Thromb Diath Haemorrh 1962;7:558–66Google Scholar
  19. 19.
    Greipp PR, Kyle RA, Bowie EJ. Factor-X deficiency in amyloidosis: a critical review. Am J Hematol 1981;11(4):443–50PubMedCrossRefGoogle Scholar
  20. 20.
    McPherson RA, Onstad JW, Ugoretz RJ, et al. Coagulopathy in amyloidosis: combined deficiency of factors IX and X. Am J Hematol 1977;3:225–35PubMedGoogle Scholar
  21. 21.
    Liebman H, Chinowsky M, Valdin J, et al. Increased fibrinolysis and amyloidosis. Arch Intern Med 1983;143(4):678–82PubMedCrossRefGoogle Scholar
  22. 22.
    Emori Y, Sakugawa M, Niiya K, et al. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis 2002;13(6):555–9PubMedCrossRefGoogle Scholar
  23. 23.
    Gertz MA, Fonseca R, Rajkumar SV. Waldenstrom's macroglobulinemia. Oncologist 2000;5(1):63–7PubMedCrossRefGoogle Scholar
  24. 24.
    Penny R, Castaldi PA, Whitsed HM. Inflammation and haemostasis in paraproteinaemias. Br J Haematol 1971;20(1):35–44PubMedCrossRefGoogle Scholar
  25. 25.
    Cohen I, Amir J, Ben-Shaul Y, et al. Plasma cell myeloma associated with an unusual myeloma protein causing impairment of fibrin aggregation and platelet function in a patient with multiple malignancy. Am J Med 1970;48(6):766–76PubMedCrossRefGoogle Scholar
  26. 26.
    DiMinno G, Coraggio F, Cerbone AM, et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986;77(1):157–64PubMedCrossRefGoogle Scholar
  27. 27.
    Zima T, Spicka I, Stípek S, et al. Antioxidant enzymes and lipid peroxidation in patients with multiple myeloma. Neoplasma 1996;43(2):69–73PubMedGoogle Scholar
  28. 28.
    Cieslar P, Masova L, Scheiner T, et al. Oxidative stress and platelet function in multiple myeloma and renal insufficiency: clinical relations of different tests. Thromb Res 2002;105(4):277–83PubMedCrossRefGoogle Scholar
  29. 29.
    Taher A, Abiad R, Uthman I. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Lupus 2003;12(11):854–6PubMedCrossRefGoogle Scholar
  30. 30.
    Mohri H, Noguchi T, Kodama F, et al. Acquired von Willebrand disease due to inhibitor of human myeloma protein specific for von Willebrand factor. Am J Clin Pathol 1987;87(5):663–8PubMedGoogle Scholar
  31. 31.
    Loftus LS, Arnold WN. Acquired hemophilia in a patient with myeloma. West J Med 1994;160(2):173–6PubMedGoogle Scholar
  32. 32.
    Eby CS. Bleeding and thrombosis risks in plasma cell dyscrasias. Hematology Am Soc Hematol Educ Program 2007;2007:158–64CrossRefGoogle Scholar
  33. 33.
    Federici AB, Mannucci PM. Diagnosis and management of acquired von Willebrand syndrome. Clin Adv Hematol Oncol 2003;1(3):169–75PubMedGoogle Scholar
  34. 34.
    Mant MJ, Hirsh J, Gauldie J, et al. Von Willebrand's syndrome presenting as an acquired bleeding disorder in association with a monoclonal gammopathy. Blood 1973;42(3):429–36PubMedGoogle Scholar
  35. 35.
    Tiede A, Priesack J, Werwitzke S, et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 2008;6:569–76PubMedCrossRefGoogle Scholar
  36. 36.
    Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc 2002;77(2):181–7Google Scholar
  37. 37.
    Shinagawa A, Kojima H, Berndt MC, et al. Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost 2005;93(5):889–96PubMedGoogle Scholar
  38. 38.
    van Genderen PJ, Vink T, Michiels JJ, et al. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994;84(10):3378–84PubMedGoogle Scholar
  39. 39.
    Brody JI, Haidar ME, Rossman RE. A hemorrhagic syndrome in Waldenstrom's macroglobulinemia secondary to immunoadsorption of factor VIII. Recovery after splenectomy. N Engl J Med 1979;300(8):408–10PubMedCrossRefGoogle Scholar
  40. 40.
    Saif MW, Allegra CJ, Greenberg B. Bleeding diathesis in multiple myeloma. J Hematother Stem Cell Res 2001;10(5):657–60PubMedCrossRefGoogle Scholar
  41. 41.
    Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol 1997;97(1):219–26PubMedCrossRefGoogle Scholar
  42. 42.
    Wisløff F, Michaelsen TE, Godal HC. Inhibition or acceleration of fibrin polymerization by monoclonal immunoglobulins and immunoglobulin fragments. Thromb Res 1984;35(1):81–90PubMedCrossRefGoogle Scholar
  43. 43.
    Lackner H, Hunt V, Zucker MB, et al. Abnormal fibrin ultrastructure, polymerization, and clot retraction in multiple myeloma. Br J Haematol 1970;18(6):625–36PubMedCrossRefGoogle Scholar
  44. 44.
    Wisløff F, Michaelsen TE, Kierulf P, et al. The molecular localization of the ability of certain monoclonal immunoglobulins to interfere with fibrin polymerization. Thromb Res 1985;40(4):473–82PubMedCrossRefGoogle Scholar
  45. 45.
    Beardell FV, Varma M, Martinez J. Normalization of plasma factor X levels in amyloidosis after plasma exchange. Am J Hematol 1997;54(1):68–71PubMedCrossRefGoogle Scholar
  46. 46.
    Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med 1995;10:128–141PubMedGoogle Scholar
  47. 47.
    Torjemane L, Guermazi S, Ladeb S, et al. Heparin-like anticoagulant associated with multiple myeloma and neutralized with protamine sulfate. Blood Coagul Fibrinolysis 2007;18(3):279–81PubMedCrossRefGoogle Scholar
  48. 48.
    Llamas P, Outeiriño J, Espinoza J, et al. Report of three cases of circulating heparin-like anticoagulants. Am J Hematol 2001;67(4):256–8PubMedCrossRefGoogle Scholar
  49. 49.
    Chapman GS, George CB, Danley DL. Heparinlike anticoagulant associated with plasma cell myeloma. AJCP 1985; 83:764–766PubMedGoogle Scholar
  50. 50.
    Kaufman PA, Gockerman JP, Greenberg CS. Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature. Am J Med 1989;86(5):612–6PubMedCrossRefGoogle Scholar
  51. 51.
    Endo T, Yatomi Y, Amemiya N, et al. Antibody studies of factor VIII inhibitor in a case with Waldenström's macroglobulinemia. Am J Hematol 2000;63(3):145–8PubMedCrossRefGoogle Scholar
  52. 52.
    Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982;60(5):1103–9PubMedGoogle Scholar
  53. 53.
    Takahashi H, Koike T, Yoshida N, et al. Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol 1986;23(2):153–66PubMedCrossRefGoogle Scholar
  54. 54.
    Liebman HA, Carfagno MK, Weitz IC, et al. Excessive fibrinolysis in amyloidosis associated with elevated plasma single-chain urokinase. Am J Clin Pathol 1992;98(5):534–41PubMedGoogle Scholar
  55. 55.
    Sane DC, Pizzo SV, Greenberg CS. Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review. Am J Hematol 1989;31(1):53–7PubMedCrossRefGoogle Scholar
  56. 56.
    Ostrowska JD, Wojtukiewicz MZ, Chabielska E, et al. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. Thromb Haemost 2004;92(1):171–177PubMedGoogle Scholar
  57. 57.
    Wang M, Giralt S, Delasalle K, et al. Bortezomib in combination with thalildomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007;12:235–239PubMedCrossRefGoogle Scholar
  58. 58.
    Avcu F, Ural AU, Cetin T, et al. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res 2008;121(4):567–71PubMedCrossRefGoogle Scholar
  59. 59.
    Zangari M, Guerrero J, Cavallo F, et al. Coagulation-related effect of bortezomib treatment in patients with relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2007; 110: Abstract 2733Google Scholar
  60. 60.
    Federici AB, Stabile F, Castaman G, et al. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998;92(8):2707–11PubMedGoogle Scholar
  61. 61.
    Hayashi T, Yagi H, Suzuki H, et al. Low-dosage intravenous immunoglobulin in the management of a patient with acquired von Willebrand syndrome associated with monoclonal gammopathy of undetermined significance. Pathophysiol Haemost Thromb 2002;32(1):33–9PubMedCrossRefGoogle Scholar
  62. 62.
    Friederich PW, Wever PC, Briët E, et al. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001;66(4):292–4PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Maurizio Zangari
    • 1
  • F. Elice
    • 2
  • G. Tricot
    • 3
  • L. Fink
    • 4
  1. 1.University of Utah, Division of Hematology, Blood/Marrow Transplant and Myeloma ProgramSalt Lake CityUSA
  2. 2.Department of HematologySan Bortolo HospitalVicenzaItaly
  3. 3.Division of HematologyBlood/ Marrow Transplant and Myeloma ProgramSalt Lake City
  4. 4.Laboratory MedicineNevada Cancer InstituteLas Vegas

Personalised recommendations